SPEXIS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0596 CHF | -0.33% |
|
-5.40% | +45.37% |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
| Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
| Sales 2021 | 331 363.9 | Sales 2022 | 1.48M 1.62M | Capitalization | 19.96M 21.95M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -12.09M | Net income 2022 | -18M -19.79M | EV / Sales 2021 * | - |
| Net cash position 2021 | 6.23M 6.85M | Net Debt 2022 | 4.23M 4.66M | EV / Sales 2022 | 16.4 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Spexis AG
More press releases
| 1 day | +8.73% | ||
| Current month | -29.65% | ||
| 1 month | -40.20% | ||
| 3 months | -53.82% | ||
| 6 months | -68.69% | ||
| Current year | +45.85% |
1 week
0.05
0.07
1 month
0.050.10
Current year
0.041.06
1 year
0.011.06
3 years
0.012.20
5 years
0.012.20
10 years
0.012.20
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.0596 | -0.33% | 16 805 |
| 24-04-17 | 0.0598 | +8.73% | 237,392 |
| 24-04-16 | 0.055 | -13.79% | 111,043 |
| 24-04-15 | 0.0638 | -1.85% | 700 |
| 24-04-12 | 0.065 | +3.17% | 541,906 |
Delayed Quote Swiss Exchange, April 17, 2024 at 11:31 am EDT
More quotes
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Sector
Pharmaceuticals
Calendar
2024-09-04
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +45.85% | 4.44M | |
| -5.32% | 84.57B | |
| +2.11% | 39.93B | |
| -25.74% | 27.93B | |
| +52.03% | 24.21B | |
| -6.17% | 17.17B | |
| -31.09% | 13.93B | |
| -6.58% | 12.3B | |
| -16.04% | 11.84B | |
| -4.19% | 7.91B |
- Stock Market
- Equities
- POLN Stock
